{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:11:22Z","timestamp":1780571482576,"version":"3.54.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"German national Network Genomic Medicine (nNGM) Lung Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncogenic alterations in MET represent therapeutically actionable driver alterations in non-small cell lung cancers (NSCLC). Among these, MET fusions are rare, occurring in approximately 0.1%-0.3% of NSCLC. We report the case of a 52-year-old woman with metastatic, TTF1-positive lung adenocarcinoma harboring a KIF5B::MET fusion. After progression on chemotherapy and immunotherapy, she achieved a durable response lasting nearly five years on third-line treatment with the type Ia MET inhibitor crizotinib. At the time of suspected disease progression, two tissue re-biopsies were non-diagnostic due of insufficient tumor cell content. Circulating tumor DNA (ctDNA) analysis identified two newly acquired on-target resistance mutations within the MET kinase domain (L1213V and Y1248C) in addition to the known KIF5B::MET fusion. After re-evaluation by the institutional molecular tumor board, both alterations were considered mediators of resistance to type I MET inhibitors, with available data indicating preserved sensitivity to type II inhibitors. Based on these findings, the patient was switched to cabozantinib, a multikinase type II MET inhibitor, resulting in a radiographic disease stabilization accompanied by a marked decline in tumor marker levels. This case illustrates the clinical utility of liquid biopsy for molecular resistance monitoring, particularly when tissue re-biopsy is not feasible, supports its integration into clinical decision-making, and underscores the therapeutic relevance of MET inhibitor class-switch strategies in MET fusion-positive disease.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag151","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:52:42Z","timestamp":1776430362000},"source":"Crossref","is-referenced-by-count":0,"title":["Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0256-7038","authenticated-orcid":false,"given":"Stanislav","family":"Rosnev","sequence":"first","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, , Berlin 12203,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Klein","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, , Berlin 12203,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Heukamp","sequence":"additional","affiliation":[{"name":"Institute for Hematopathology Hamburg , Hamburg 22547,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Lenk","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Radiology, , Berlin 12203,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Joosten","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Institute of Pathology, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-3032","authenticated-orcid":false,"given":"Markus","family":"M\u00f6bs","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Institute of Pathology, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Grob","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Institute of Pathology, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Benary","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Core Unit Bioinformatics, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Vecchione","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, , Berlin 12203,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3627-3791","authenticated-orcid":false,"given":"Claus-Eric","family":"Ott","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Institute for Medical and Human Genetics, Campus Virchow-Klinikum, , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik P","family":"Modest","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, , Berlin 12203,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Kn\u00f6dler","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, , Berlin 12203,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin 10117,","place":["Germany"]},{"name":"Max-Delbr\u00fcck-Center for Molecular Medicine , Berlin 13125,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Cluster of Excellence ImmunoPreCept, , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-7129","authenticated-orcid":false,"given":"Nikolaj","family":"Frost","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Infectious Diseases and Pulmonary Medicine, , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Kiewe","sequence":"additional","affiliation":[{"name":"Onkologischer Schwerpunkt am Oskar-Helene-Heim , Berlin 14195,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0027-7977","authenticated-orcid":false,"given":"Damian T","family":"Rieke","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, , Berlin 12203,","place":["Germany"]},{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin Comprehensive Cancer Center, , Berlin 10117,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin 10117,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026060406344413700_oyag151-B1","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.1002\/cam4.6047","article-title":"Molecular characterization of MET fusions from a large real-world Chinese population: a multicenter study","volume":"12","author":"Xia","year":"2023","journal-title":"Cancer Med"},{"key":"2026060406344413700_oyag151-B2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2159-8290.CD-24-0417","article-title":"Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy","volume":"15","author":"Febres-Aldana","year":"2025","journal-title":"Cancer Discov"},{"key":"2026060406344413700_oyag151-B3","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.jtocrr.2023.100630","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"2026060406344413700_oyag151-B4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"2026060406344413700_oyag151-B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2023.01.017","article-title":"Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer","volume":"178","author":"Kang","year":"2023","journal-title":"Lung Cancer"},{"key":"2026060406344413700_oyag151-B6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jtho.2016.09.119","article-title":"Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping","volume":"12","author":"Ou","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026060406344413700_oyag151-B7","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.jtho.2017.10.028","article-title":"Osimertinib and cabozantinib combinatorial therapy in an EGFR-mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to crizotinib","volume":"13","author":"Kang","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026060406344413700_oyag151-B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejca.2022.11.010","article-title":"Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors","volume":"179","author":"Riedel","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026060406344413700_oyag151-B9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026060406344413700_oyag151-B10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors In vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026060406344413700_oyag151-B11","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.3390\/curroncol30100635","article-title":"The combined therapy of cabozantinib, crizotinib, and osimertinib in a lung cancer patient with acquired MET amplification and resistance mutations","volume":"30","author":"J\u00f3ri","year":"2023","journal-title":"Curr Oncol"},{"key":"2026060406344413700_oyag151-B12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12964-023-01454-0","article-title":"MET fusions are targetable genomic variants in the treatment of advanced malignancies","volume":"22","author":"Sun","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2026060406344413700_oyag151-B13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/PAS.0000000000001065","article-title":"Salivary secretory carcinoma with a novel ETV6-MET fusion: Expanding the molecular spectrum of a recently described entity","volume":"42","author":"Rooper","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2026060406344413700_oyag151-B14","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1634\/theoncologist.2020-0502","article-title":"Tepotinib efficacy in a patient with Non-Small cell lung cancer with brain metastasis harboring an HLA-DRB1-MET gene fusion","volume":"25","author":"Blanc-Durand","year":"2020","journal-title":"Oncologist"},{"key":"2026060406344413700_oyag151-B15","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.21037\/tcr-22-141","article-title":"Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report","volume":"11","author":"Liu","year":"2022","journal-title":"Transl Cancer Res"},{"key":"2026060406344413700_oyag151-B16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.lungcan.2016.11.006","article-title":"Response and acquired resistance to crizotinib in chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations","volume":"102","author":"Dong","year":"2016","journal-title":"Lung Cancer"},{"key":"2026060406344413700_oyag151-B17","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-Mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026060406344413700_oyag151-B18","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1158\/1078-0432.CCR-16-3273","article-title":"Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026060406344413700_oyag151-B19","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1158\/1535-7163.MCT-13-0151","article-title":"The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants","volume":"12","author":"Medov\u00e1","year":"2013","journal-title":"Mol Cancer Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag151\/68131988\/oyag151.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag151\/68131988\/oyag151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag151\/68131988\/oyag151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:34:48Z","timestamp":1780569288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag151\/8660469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag151","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,21]]},"article-number":"oyag151"}}